1752 — Nang Kuang Pharmaceutical Co Income Statement
0.000.00%
Last trade - 00:00
- TWD4.75bn
- TWD4.82bn
- TWD2.15bn
- 65
- 39
- 55
- 53
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1,762 | 1,755 | 1,780 | 1,940 | 2,150 |
Cost of Revenue | |||||
Gross Profit | 622 | 597 | 594 | 695 | 756 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 1,516 | 1,532 | 1,519 | 1,619 | 1,958 |
Operating Profit | 246 | 223 | 261 | 322 | 192 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 251 | 224 | 235 | 411 | 214 |
Provision for Income Taxes | |||||
Net Income After Taxes | 217 | 183 | 196 | 352 | 198 |
Net Income Before Extraordinary Items | |||||
Net Income | 217 | 183 | 196 | 352 | 198 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 217 | 183 | 196 | 352 | 198 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 2.17 | 1.81 | 1.94 | 3.48 | 2.52 |
Dividends per Share |